Secondary Outcome(s)
|
Change From Baseline in Patient Determined Disease Steps (PDDS) Scale Total Score at Month 6, 12 and 24
[Time Frame: Baseline (Month 0), Month 6, 12 and 24]
|
Elapsed Time to Discontinuation After First Dose of Cladribine Tablets
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Percentage of Planned Doses Received by Participants as per United States Prescribing Information
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Number of Participants With Adherence to Treatment as Assessed by Modified Versions of the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)
[Time Frame: Baseline (Month 0) and at the end of Months 1, 2, 13 and 14]
|
Number of Participants With Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Adverse Events of Special Interest (AESIs) and Special Situations
[Time Frame: Baseline (Month 0) up to 24 months]
|
Change From Baseline in 7-Item Beck-Depression Inventory-Fast Screen (BDI-FS) Total Score at Month 6, 12 and 24
[Time Frame: Baseline (Month 0), Month 6, 12 and 24]
|
Number of Doses Received by Participants as per United States Prescribing Information
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Percentage of Participants With Reason for Discontinuation of Cladribine Tablets
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Change From Baseline in 14-Item Treatment Satisfaction Questionnaire for Medication (TSQM-14) Total Score at Month 6, 12 and 24
[Time Frame: Baseline (Month 0), Month 6, 12 and 24]
|
Annualized Relapse Rate (ARR) (Retrospective Assessment)
[Time Frame: Up to 24 Months prior Baseline (Month 0)]
|
Percentage of Participants With Relapse Associated With Glucocorticoid Use
[Time Frame: Month 12 and 24]
|
Change From Baseline in 6-Item Work Productivity Activity Impairment - Multiple Sclerosis (WPAI-MS) Total Score at Month 6, 12 and 24
[Time Frame: Baseline (Month 0), Month 6, 12 and 24]
|
Number of Participants Assessed of Concomitant Multiple Sclerosis Medications Used During Study Period
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Change From Baseline in Modified Fatigue Impact Scale - 5-item version (MFIS-5) Total Score at Month 6, 12 and 24
[Time Frame: Baseline (Month 0), Month 6, 12 and 24]
|
Number of Participants with Subsequent Treatment Chosen Following Discontinuation of Cladribine Tablets
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Treatment Pattern as Evaluated by Number of Participants With Previous Treatment for Multiple Sclerosis (MS)
[Time Frame: At Baseline (Month 0)]
|
Percentage of Participants with Relapse (Prospective Assessment)
[Time Frame: Month 12 and 24]
|
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Total Score at Month 6, 12 and 24
[Time Frame: Baseline (Month 0), Month 6, 12 and 24]
|
Percentage of Participants Who Discontinue Cladribine Tablets
[Time Frame: Baseline (Month 0) up to 24 Months]
|
Percentage of Participants With Relapse Associated With Hospitalization, Diagnosis or Reason for Hospitalization
[Time Frame: Month 12 and 24]
|